← Back to Search

Device

Spinal Cord Stimulation for Type 2 Diabetes

N/A
Recruiting
Led By Kim Burchiel, MD
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects who are already planning to undergo SCS for pain
Persistent neuropathic leg and back pain
Must not have
Subjects with a BMI of <25 or >45
Decisionally impaired adults
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week
Awards & highlights

Summary

This trial will investigate whether or not SCS can help with weight loss and diabetes.

Who is the study for?
This trial is for adults aged 21-70 with persistent neuropathic leg and back pain who are planning to get spinal cord stimulation (SCS) for pain relief. They should not have tried SCS before, have a BMI between 25-45, and haven't had significant weight changes recently. Excluded are pregnant individuals, tobacco or excessive alcohol users, those on beta blockers, or anyone outside the BMI range.
What is being tested?
The study aims to see if using spinal cord stimulation can help with weight loss and improve Type 2 diabetes by boosting metabolism in fat tissue. Participants will receive an experimental research electrode during their planned SCS procedure.
What are the potential side effects?
Potential side effects may include discomfort at the electrode site, possible infection risk from the procedure, changes in sensation due to nerve stimulation, and any typical risks associated with surgical procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am planning to get a spinal cord stimulator for pain.
Select...
I have ongoing nerve pain in my leg and back.
Select...
I have never tried a spinal cord stimulator for pain.
Select...
I am between 21 and 70 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My BMI is either below 25 or above 45.
Select...
I am considered unable to make my own medical decisions.
Select...
I am currently taking beta blockers.
Select...
I am under 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
SUVmax
Secondary study objectives
Ipsi- and contralateral BAT during SCS-activation

Trial Design

1Treatment groups
Experimental Treatment
Group I: All subjectsExperimental Treatment1 Intervention
All subjects will have two PET/CT scans on days 3 and 5 after SCS electrode implantation: (1) Baseline and (2) SCS-activated. Other than SCS activation, both studies will be conducted under identical conditions. For the first scan, subjects will be randomly assigned to either a baseline (no SCS during PET/CT) or with SCS during PET/CT prior to the day of their first scan. The second scan will complete the sequence with either a baseline or SCS-activated scan, as randomized.

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
994 Previous Clinical Trials
7,386,938 Total Patients Enrolled
Kim Burchiel, MDPrincipal InvestigatorOregon Health and Science University

Media Library

Research electrode (Device) Clinical Trial Eligibility Overview. Trial Name: NCT04326192 — N/A
Type 2 Diabetes Research Study Groups: All subjects
Type 2 Diabetes Clinical Trial 2023: Research electrode Highlights & Side Effects. Trial Name: NCT04326192 — N/A
Research electrode (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04326192 — N/A
~2 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top